Sai Life Sciences has recently informed exchanges that the company successfully commenced commercial operations of the second phase of its production block at the Unit IV facility in Bidar, Karnataka, as of June 19, 2025. This phase adds around 91 kL of manufacturing capacity, marking the completion of the company’s planned 195 kL expansion project at the site, as outlined in its prospectus.
With this addition, the total installed capacity at the Bidar facility now stands at approximately 640 kL. The expanded unit is fully equipped to manufacture Registered Starting Materials (RSMs), intermediates, and Active Pharmaceutical Ingredients (APIs), catering to both clinical development and commercial-scale supply.
This strategic milestone strengthens Sai Life Sciences’ manufacturing footprint and aligns with its long-term growth plans in the pharmaceutical sector. The company’s enhanced infrastructure will support its global clientele with high-quality and scalable production capabilities.
